Immuron Limited · ASX:IMC
Immuron — Shareholder Meeting (November 2012)
24 slides from Immuron's shareholder meeting presentation, Nov 26, 2012
Slide 1: Chairman's address to Annual General Meeting
ABN: 80 063 114 045 Level 1 18 Kavanagh Street Southbank, Vic 3006 Tel: +61 3 8648 4530 Fax: +61 3 9686 9460 www.immuron.com For personal use only 26 November 2012 Chairman’s address to Annual General Meeting 26 November 2012. Ladies and Gentlemen good morning and welcome to the Immuron AGM. My name
Slide 2: For personal use only
Firstly What a great opportunity for a turn-around story – the company is clearly unloved by the market; For personal use only they have a product on the market and a product pipeline that could potentially make this a 50-100 million dollar company; the products have a wonderfully simple manuf
Slide 3: For personal use only
I think one thing that was probably not fully anticipated by Immuron historically were the timelines associated with approval, licensing and launch of new products by third parties; however, let’s not throw the baby out with the bathwater, we are nearly at the finish line, and we need to gather stre
Slide 4: Annual General Meeting November 2012
For personal use only Annual General Meeting 26 November 2012 AGM 2012
Slide 5: Strategy for Turnaround
STRATEGY FOR TURNAROUND For personal use only MANUFACTURE TO GMP NYCOMED TRAVELAN FDA NASH LAUNCH AUS IND GRANTED PALADIN HARVARD CANADA MUCOSITIS HADASIT PATENT ACQUISITION INFLUENZA AGM 2012
Slide 6: For personal use only
For personal use only Company Update AGM 2012
Slide 7: Forward Looking Statement
For personal use only FORWARD LOOKING STATEMENT This presentation and Immuron’s accompanying comments and explanations may include forward‐looking statements including statements containing words such as “may”, “expect”, “believe”, and “intend”, and may describe opinions about future events. We have
Slide 8: About
ABOUT For personal use only • Melbourne based biopharmaceutical company • Publicly listed on the Australian Stock Exchange (ASX: IMC) • Focuses on Oral Immunotherapy using dairy‐derived antibodies • Superior safety profile products makes it possible to accelerate product development • First product
Slide 9: Technology and Product Highlights
TECHNOLOGY AND PRODUCT HIGHLIGHTS For personal use only Safe Technology – Hyper Immune Colostrum Current in‐market product sold ~200,000 units with no adverse events reported Proven Platform Technology Travelan launched successfully in Australia as an OTC medication for the treatment of travellers’
Slide 10: Highlights 2012
HIGHLIGHTS 2012 For personal use only • Board changes: commercial focus, manufacturing • Capital raising • Travelan • 9 expanded territories in Asia • Paladin Labs submitted to Health Canada for approval • Commenced US licencing discussions • NASH/Fatty Liver • IND accepted by FDA • ASH study to be
Slide 11: Board Changes
BOARD CHANGES For personal use only The Board: Dr Roger Aston (Chairman from Oct 2012) Dr Elane Zelcer (Sep 2010) Dr Stewart Washer (Feb 2012) Mr Daniel Pollock (Oct 2012) Mr Joe Baini (May 2012) • Extensive commercial experience • Strong manufacturing acumen • Biotechnology experience • Capital rai
Slide 12: Management - Increased Depth
MANAGEMENT ‐ INCREASED DEPTH For personal use only Quality Manager: • contracted to correct and complete all necessary production processes in preparation for scale‐up IP: • patent applications continue to progress Project Manager: • co‐ordinates all elements across the operations of the company, in
Slide 13: Management Team
MANAGEMENT TEAM For personal use only Joe Baini, CEO & Managing Director • Experienced pharmaceutical executive; former GM for Gilead Sciences & non‐exec chairman for Avexa Ltd Mr Graeme Stevens, Chief Financial Officer & Company Secretary • Qualified Chartered Accountant; more than 30 years profess
Slide 14: Capital Raising
CAPITAL RAISING For personal use only • Engaged Patersons Securities, one of Australia’s leading brokerage firm • Led a $1m capital raising • fully subscribed • Share purchase plan • opportunity for existing shareholders to participate • raised additional $442,050 • Bonus options included, with an e
Slide 15: Travelan - Expanding Territories
TRAVELAN – EXPANDING TERRITORIES For personal use only Expanded Asian territories: >20% global travel destination in 2011 • Cambodia • China • Hong Kong • Laos • Malaysia • Singapore • Taiwan • Thailand • Vietnam • Canada/Paladin: submission to Health Canada early this year; approval expected shortl
Slide 16: Travelan - Product on the Market
Travelan – Product on the Market For personal use only • Antibodies directed against bacteria that cause travellers’ diarrhoea • TGA approved, sales in Australia (volume growth of 112% over previous financial year) • Unique preventative oral immune therapeutic (with lower claims due to listing as di
Slide 17: www.travelan.com.au
www.travelan.com.au For personal use only AGM 2012
Slide 18: NASH Progress
NASH PROGRESS For personal use only FDA: • IND approval January 2012 • Supportive and helpful feedback • Further “visibility” on Phase III NASH endpoints Large pharmaceutical companies: • Met and presented to several • Positive responses from all • General consensus for validation study Pursuing dua
Slide 19: NASH - Pathway with Reduced Risk
NASH – PATHWAY WITH REDUCED RISK For personal use only Immuron’s De-Risked Traditional NCE Platform Pre‐clinical Pre‐clinical Phase I clinical Phase I clinical OR OTC Consumer Phase II clinical Phase II clinical OR OTC Consumer Phase III clinical Phase III clinical OR Medical Prescribed Prescribed f
Slide 20: Alcoholic Steatohepatitis - ASH
ALCOHOLIC STEATOHEPATITIS ‐ ASH For personal use only • Cause & progression may differ from NASH but: • Histologically identical • Both characterized by fatty deposits on the liver, inflammation and liver deterioration • Treatment: Same for both conditions • Funding: Principal investigator for Immur
Slide 21: R&D Program
R&D PROGRAM For personal use only Influenza in final ferrets trial • Using latest California 7 strain • Study commenced November 5 • Supported by Federal Government Grants C. Difficile • Preclinical study with Monash University • Supported by Federal Government Grant Harvard Medical School • Radiati
Slide 22: Product Pipeline
PRODUCT PIPELINE For personal use only AGM 2012
Slide 23: 2013 Imperatives
2013 IMPERATIVES For personal use only US License Agreement Capital Raising Immediate revenue stream NASH validation Further validation of study/trials commence Immuron’s technology & value Hadassah’s collaboration = future pipeline Operations Opens doors to other significant territories AGM 2012
Slide 24: Summary
Summary For personal use only • Oral Immunotherapy Using Antibodies • Strong Intellectual Property • Tight Collaboration with Key Research Partners • Key Alliance with Global Pharmaceutical Company • Proven, Novel Technology – Hyper Immune Colostrum (HIC) • Innovation Commercialized Product: Travela